Theranostic Outcomes in Clinical Practice of Oncology: What,So What,Now What? What's More

Sartor O , de Bono JS . Metastatic prostate cancer. N Engl J Med, 2018; 378:645.

Salles GA , Seymour JF , Feugier P , et al. Long-term follow-up of the PRIMA study. Half of patients receiving rituximab maintenance remain progression-free at 10 years. Blood 2017;130suppl 1:Abstract 486.

Morschhauser F , Fowler NH , Feugier P , et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma N Engl J Med 2018; 379:934.

Kim J , Singh H , Ayalew K , et al. Use of patient reported outcome measures to inform tolerability in oncology trials: Implications for clinical review, IND, safety reporting and clinical site inspections. Clin Cancer Res, 2018; 24:1780.

Basch E . Patient-reported outcomes: An essential component of oncology drug development and regulatory review. Lancet Oncol, 2018; 19:595.

Ma CKK , Danta M , Day R , et al. Dealing with the spiralling price of medicines: Issues and solutions. Intern Med J, 2018; 48:16.

Cherny NI , de Vries EGE , Dafni U , et al. Comparative assessment of clinical benefit using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score. J Clin Oncol, 2019; 37:336.

Nishino M , Ramaiya NH , Hatabu H , et al. Monitoring immune-checkpoint blockade: Response evaluation and biomarker development. Nat Rev Clin Oncol, 2017; 14:655.

Gerwing M , Herrmann K , Helfen A , et al. The beginning of the end for conventional RECIST; novel therapies require novel imaging approaches. Nat Rev Clin Oncol, 2019 [Epub ahead of print]; DOI:10.1038/s41571-019-0169-5.

Romero D . To all involved—We have a problem. Nat Rev Clin Oncol, 2018; 15:397.

Uyl-de Groot CA , Lowenberg B . Sustainability and affordability of cancer drugs: A novel pricing model. Nat Rev Clin Oncol, 2018; 15:405.

Gross CP , Gluck AR . Soaring cost of cancer treatment: Moving beyond sticker shock. J Clin Oncol, 2018; 36:305.

Postow MA , Sidlow R , Hellmann MD . Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med, 2018; 378:158.

Turner JH . An introduction to the clinical practice of theranostics in oncology. Br J Radiol, 2018; 91:20180440.

Kaminski MS , Tuck M , Estes J , et al. Iodine-131-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med, 2005; 352:441.

Kaminski MS , Estes J , Zasadny KR , et al. Radioimmunotherapy with iodine-131-tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood, 2000; 96:1259.

Green DJ , Press OW . Whither radioimmunotherapy: To be or not to be?. Cancer Res, 2017; 77:2191.

SNMMI and NC. I Theranostics consensus conference 2018. J Nucl Med, 2019;60:7N.

Leahy MF , Turner JH . Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with I-131-rituximab in routine clinical practice: 10-year single institution experience of 142 consecutive patients. Blood, 2011; 117:45.

McQuillan AD , Macdonald WBG , Turner JH . Phase 2 study of first-line I-131-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic F-18-fluorodeoxyglucose positron emission tomography. Leuk Lymphoma, 2015; 56:1271.

Brabander T , van der Zwan WA , Jaap JM , et al. Long-term efficacy, survival, and safety of (177-Lu-DOTA, Tyr3) octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res, 2017; 23:4617.

Strosberg J , El-Haddad G , Wolin E , et al. Phase 3 trial of 177-Lu-dotatate for mid-gut neuroendocrine tumors. N Engl J Med, 2017; 376:125.

Van der Zwan WA , Brabander T , Kam BLR , et al. Salvage peptide receptor radionuclide therapy with (177-Lu-DOTA,Tyr3) octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging, 2019; 46:704.

Kong G , Thompson M , Collins M , et al. Assessment of prediction of response and long-term survival of patients with neuroendocrine tumors treated with peptide receptor chemo-radionuclide therapy (PRCRT). Eur J Nucl Med Mol Imaging, 2014; 41:1831.

Claringbold PG , Brayshaw PA , Price RA , et al. Phase 2 study of radiopeptide 177-Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumors. Eur J Nucl Med Mol Imaging, 2011; 38:302.

Hofman MS , Michael M , Hicks RJ . Lu-177-dotatate for mid-gut endocrine tumors. N Engl J Med, 2017; 376:1390.

Strosberg J , Wolin E , Chasen B , et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177-Lu-dotatate in the phase 3 NETTER-1 trial. J Clin Oncol, 2018; 36:2578.

Marinova M , Mucke M , Mahlberg L , et al. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. Eur J Nucl Med Mol Imaging, 2018; 45:38.

Strosberg JR , Fine RL , Choi J , et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011; 117:268.

Claringbold PG , Turner JH . Pancreatic neuroendocrine tumor control: Durable objective response to combination 177-Lu-octreotate-capecitabine-temozolomide radiopeptide chemotherapy. Neuroendocrinol, 2016; 103:4329.

Kulkarni HR , Singh A , Schuchardt C , et al. Theranostics of prostate cancer: From molecular imaging to precision molecular radiotherapy targeting the prostate-specific membrane antigen. Br J Radiol, 2018; 91:20180308.

Rahbar K , Ahmadzadehfar H , Kratochwil C , et al. German multicentre study investigating 177-Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med, 2017; 58:85.

Hofman MS , Violet J , Hicks RJ , et al. (177-Lu)-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet Oncol, 2018; 19:825.

Thompson CA , Novotny PJ , Bartz A , et al. Development of novel emoji scale to measure patient-reported outcomes in cancer patients. J Clin Oncol, 2018;36:Abstract 174.

Kratochwil C , Bruchertseifer F , Rathke H , et al. Targeted alpha therapy of metastatic castrate-resistant prostate cancer with 225-Ac-PSMA-617: Swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med, 2018; 59:795.

Roach PJ , Francis R , Emmett L , et al. The impact of 68-Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicentre study. J Nucl Med, 2018; 59:82.

Lenzo NP , Meyrick D , Turner JH . Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer. Diagnostics 2018 [Epub ahead of print]; DOI: 10.3390/diagnostics 8010016.

Beheshti M , Paymani Z , Brilhante J , et al. Optimal time-point for 68_Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: Feasibility of sterile cold-kit tracer preparation?. Eur J Nucl Med Mol Imaging, 2018; 45:1188.

Jarow JP , La Vange L , Woodcock J , et al. Multidimensional evidence generation and FDA regulatory decision making; defining and using ‘real world data’. JAMA, 2017; 318:703.

Food and Drug Administration. Statement from FDA Commissioner Scott Gottliebe MD on FDA's new strategic framework to advance use of real-world evidence to support development of drugs and biologics. FDA. Online document at https://www.fda.gov/NewsEvents Newsroom/Press Announcements/ucm 627760.htm.2018 December 06 2018.

Hall PS . Real-world data for efficient health technology assessment. Eur J Cancer, 2017; 79:235.

Booth CM , Karim S , Mackillop WJ , et al. Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol 2019 [Epub ahead of print]; DOI: 10.1038/s41571-019-0167-7.